Longevity Medicine
Moderate EvidenceAMPK activation and the TAME trial — diabetes drug as longevity intervention.
Evidence-based guide to metformin dosing in CKD patients. eGFR cutoffs, lactic acidosis risk, FDA label changes, and how longevity physicians adjust protocol for renal impairment.
Head-to-head comparison of berberine and metformin for glucose control, lipids, and longevity. Both activate AMPK — but how do they really compare?
Complete guide to metformin side effects in non-diabetics using it for longevity. B12 depletion, GI issues, exercise blunting, muscle loss risk, and mitigation strategies.
Head-to-head comparison of metformin and berberine for longevity, AMPK activation, blood sugar, and exercise compatibility. Evidence, dosing, and which to choose.
A physician's honest comparison of rapamycin and metformin for longevity. mTOR inhibition vs AMPK activation, evidence quality, dosing, and who should use which.
Evidence-based metformin dosing for anti-aging in non-diabetics. The TAME trial, MILES study dosages, titration protocols, and what physicians actually prescribe off-label.
Can a diabetes drug slow aging? The TAME trial, mechanistic rationale, and honest assessment of metformin as a longevity intervention.
